Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222917 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
A Phase 2 study of Chronic Kidney Disease and Hypertension, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 218
- Enrollment target
- 20
- Study locations
NCT07222917 is a Phase 2 study of Chronic Kidney Disease and Hypertension that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 218 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT07222917, a Phase 2 study of Chronic Kidney Disease and Hypertension, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 218 participants
- Enrollment target
- 20
- Study locations
Study Summary
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
Conditions Studied
Interventions
- DRUG Baxdrostat/dapagliflozin
- DRUG Baxdrostat/Placebo
Study Locations (20)
Florida
- Research Site - Hollywood
- Research Site - Port Charlotte
- Research Site - Port Orange
North Carolina
- Research Site - Greenville
- Research Site - Jacksonville
- Research Site - New Bern
Texas
- Research Site - Arlington
- Research Site - Pasadena
- Research Site - San Antonio
Other
- Research Site - Buenos Aires
- Research Site - Ciudad de Buenos Aires
Arizona
- Research Site - Surprise
Georgia
- Research Site - Atlanta
Illinois
- Research Site - Champaign
Kansas
- Research Site - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2027-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07222917
The ClinicalTrials.gov registry entry for NCT07222917 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Kidney Disease and Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Baxdrostat/dapagliflozin is the first listed.
NCT07222917 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT07222917 about?
NCT07222917 is a clinical study titled "A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.". International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
What is the current status of trial NCT07222917?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2025-12-05. Estimated completion is 2027-05-24.
What conditions does trial NCT07222917 study?
This clinical trial studies the following conditions: Chronic Kidney Disease and Hypertension.
What interventions are being tested in trial NCT07222917?
The interventions under investigation include: Baxdrostat/dapagliflozin (DRUG), Baxdrostat/Placebo (DRUG).
Who is sponsoring clinical trial NCT07222917?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222917 being conducted?
This trial has 20 study locations across Arizona, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease and Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
RECRUITING · Phase 3
-
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.